Advancing the precision management of inflammatory bowel disease in the era of omics approaches and new technology.

There is great heterogeneity among inflammatory bowel disease (IBD) patients in terms of pathogenesis, clinical manifestation, response to treatment, and prognosis, which requires the individualized and precision management of patients. Many studies have focused on prediction biomarkers and models for assessing IBD disease type, activity, severity, and prognosis. During the era of biologics, how to predict the response and side effects of patients to different treatments and how to quickly recognize the loss of response have also become important topics. Multiomics is a promising area for investigating the complex network of IBD pathogenesis. Integrating numerous amounts of data requires the use of artificial intelligence.
Competing Interests: Conflict-of-interest statement: The authors declare no conflicts of interest.
(©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.)